Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Data from 29 patients with recurrent ovarian cancer in the Phase I portion of an open-label, international Phase I/II trial
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury